Editorial: New Insights on Bruton's Tyrosine Kinase Inhibitors

Front Immunol. 2021 Nov 23:12:804735. doi: 10.3389/fimmu.2021.804735. eCollection 2021.

Authors

C I Edvard Smith¹, Jennifer R Brown², Rula Zain^{1

3}

Affiliations

¹ Biomolecular and Cellular Medicine, Clinical Research Center, Department of Laboratory Medicine, Karolinska Institutet (KI), Huddinge, Sweden.
² Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, MA, United States.
³ Department of Clinical Genetics, Center for Rare Diseases, Karolinska University Hospital, Stockholm, Sweden.

No abstract available

Keywords: BTK; Waldenström’s macroglobulinemia; autoimmunity; ibrutinib; inhibitors; leukemia; lymphoma; structure-function.

Publication types

Editorial
Introductory Journal Article
Research Support, Non-U.S. Gov't

MeSH terms

Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors*
Animals
Antineoplastic Agents / pharmacology*
Enzyme Inhibitors / pharmacology*
Humans
Leukemia / drug therapy*
Lymphoma / drug therapy*

Substances

Antineoplastic Agents
Enzyme Inhibitors
Agammaglobulinaemia Tyrosine Kinase